Estrogen Receptor Status

Goulding, H., Finder, S., Cannon, P., Pearson, D., Nicholson, R., Snead, D., Bell, J., Elston, C. W., Robertson, J. E., Blarney, R. W., et al. (1995) A new immuno-histochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples. Hum. Pathol. 26, 291-294. 

Harvey, J. M., Cark, G. M., Osborne, C. K., and Allred, D. C. 1991. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol. 27 1474-1481. 

Jiang, X. P., Yang, D. C., Elliot, R. L., and Head, J. F. 1999. Reduction in serum IL-6 after vaccination of breast cancer patients with tumor-associated antigens is related to estrogen receptor status. Cytokine 72 458 165. 

Reiner, A., Reiner, G., Spona, J., Teleky, B., Kolb, R., and Holzner, J. H. 1987. Estrogen receptor immunocytochemistry for preoperative determination of estrogen receptor status on fine-needle aspirates of breast cancer. Am. J. Clin. Pathol. 88 399-404. 

Olsen, A., Knudsen, K.E.B., Thomsen, B.L., Loft, S., Stripp, C., Overvad, K., Moller, S., and Tjonneland, A. 2004. Plasma enterolactone and breast cancer incidence by estrogen receptor status. Cancer Epidemiol. Biomarkers Prev. 13, 2084—2089. 

Bardou, V.-J., Arpino, G., Elledge, R.M., Osborne, C.K., and Clark, G.M. 2003. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J. Clin. Oncol. 21, 1973-1979. 

Hoyer, A.P., Jorgensen, T., Rank, F., Grandjean, P., 2001. Organochlorine exposures influence on breast cancer risk and survival according to estrogen receptor status A Danish cohort-nested case-control study. BMC Cancer 1, 8-10. 

Gruvberger S, Ringner M, Chen Y, Panavally S, Saal LH, Borg A, Femo M, Peterson C, Meltzer PS. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 2001 61 5979-5984. 

K15. Konishi, N., Nakaoka, S., Hiasa, Y., Kitahori, Y., Oshima, M., etal, Immunohistochemical evaluation of estrogen receptor status in benign prostatic hypertrophy and in prostate carcinoma and the relationship to efficacy of endocrine therapy. Oncology 50, 259-263 (1993). 

Nichols GE, Frierson HF, Boyd JC, Hanigan MH. Automated immunohistochemical assay for estrogen receptor status in breast cancer using monoclonal antibody CC4-5 on the Ventana ES. Am J CHn Pathol 1996 106 332-38. 

All treatment group comparisons were performed first in all patients and then in breast cancer patients only. We also considered the subsets of breast cancer patients defined by low relapse risk and estrogen receptor status, although the sample sizes of these groups precluded adjusted analyses. 

Event-free survival by estrogen receptor status and treatment group in low risk, breast cancer patients only... 

Crowe JP, Hubay CA, Pearson OH, et al. Estrogen receptor status as a prognostic indicator for stage 1 breast cancer patients. Breast Cancer Res Treat. 1982 2 171-176. 

Reiner A, Reiner G, Spona J, et al. Histopathologic characterization of human breast cancer in correlation with estrogen receptor status. A comparison of immunocytochemical and biochemical analysis. Cancer. 1988 61 1149-1154. 

Goulding H, Pinder S, Cannon P, et al. A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples. Hum Pathol. 1995 26 291-294. 

G., Relation between estrogen receptor status and response to oophorectomy in advanced breast cancer. Breast Cancer Res. Treat. 8(1), 90 (1986). 

H7. Hilf, R., Feldstein, M. L Savlov, E. D., Gibson, S. L., and Seneca, B., The lack of relationship between estrogen receptor status and response to chemotherapy. Cancer (Philadelphia) 46, 2797-2800 (1980). 

Kamby, C., Rasmussen, B. B., and Kristensen, B., Estrogen receptor status of primary breast carcinomas and their metastases. Relation to pattern of spread and survival after recurrence. Br. J. Cancer 60, 252-257 (1989). 

M6. McClelland, R. A., Berger, U., Wilson, P., Powles, T. J., Trott, P. A., Easton, D., Gazet, J.-C., and Coombes, R. C., Presurgical determination of estrogen receptor status using immunocyto-chemically stained fine needle aspirate smears in patients with breast cancer. Cancer Res. 47(22), 6118-6122 (1987). 

Nesaretnam, K., Stephen, R., Dils, R. and Darbre, P. (1998) Tocotrienols inhibit the growth of human breast cancer cells irrespective of estrogen receptor status. Lipids, 33, 461 169. 

Tapparelli, C., Mettemich, R., Ehrhardt, C., Zurini, M., Claeson, G., Scully, M.F., Stone, S.R. In vitro and in vivo characterization of a neutral boron-containing thrombin inhibitor. J. Biol. Chem. 1993 268 4734-4741. Touillaud, M.S., Pillow, P.C., Jakovljevic, J., Bondy, M.L., Singletary, S.E., Li, D., Chang, S. Effect of dietary intake of phytoestrogens on estrogen receptor status in premenopausal women with breast cancer. Nutr. Cancer. 2005 51 162-169. 

---